Daniel Patrick O'Day, Director, Chairman & Chief Executive Officer, on June 01, 2026, sold 15,000 shares in Gilead Sciences (GILD) for $1,971,847. Following the Form 4 filing with the SEC, O'Day has control over a total of 617,567 common shares of the company, with 617,567 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/882095/000163864326000022/xslF345X05/wk-form4_1780437841.xml
Stephanie Disher, Director, Chief Executive Officer, on June 01, 2026, sold 25,652 shares in Atmus Filtration Technologies (ATMU) for $1,160,676. Following the Form 4 filing with the SEC, Disher has control over a total of 363,024 common shares of the company, with 363,024 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1921963/000197679226000008/xslF345X05/wk-form4_1780438980.xml
Andrew Reardon, Chief Legal Officer & Secretary, on June 01, 2026, sold 5,000 shares in Ligand Pharmaceuticals (LGND) for $1,135,316. Following the Form 4 filing with the SEC, Reardon has control over a total of 41,382 common shares of the company, with 41,382 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/886163/000200101126000083/xslF345X05/edgardoc.xml
J. E. Davis, Director, Chief Executive Officer and President, on June 01, 2026, sold 10,000 shares in Quest Diagnostics (DGX) for $1,941,400. Following the Form 4 filing with the SEC, Davis has control over a total of 132,423 common shares of the company, with 132,423 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1022079/000159983726000005/xslF345X05/wk-form4_1780439916.xml